Organization
The Kinghorn Cancer Centre
11 abstracts
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,
Abstract
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,
Abstract
Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples.Org: ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, The University of Sydney, Westmead and Blacktown Hospitals,
Abstract
A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Princess Alexandra Hospital and Faculty of Medicine at University of Queensland,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 Implementation Study).Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, Chris O'Brien Lifehouse, Camperdown, NSW, Australia,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,
Abstract
Cancer survivorship: Patient experiences on early phase trials during the COVID-19 pandemic—Qualitative study from an Australian Phase 1 unit.Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, NSW Health Pathology, Australian Catholic University,